Recent Updates
Recently added Catalysts
RARE

Ultragenyx Announces Approval of Dojolvi (triheptanoin) in Brazil for the Treatment of Long-chain Fatty Acid Oxidation Disorders in Adults and Children

Monday, August 23, 2021 1 min read
Key Takeaway: Ultragenyx Announces Approval of Dojolvi (triheptanoin) in Brazil for the Treatment of Long-chain Fatty Acid Oxidation Disorders in Adults and Children

Full Press Release Details

Ultragenyx Announces Approval of Dojolvi (triheptanoin) in Brazil for the Treatment of Long-chain Fatty Acid Oxidation Disorders in Adults and Children.
Tags: RARE Viatris Investor Conferences Healthcare investor conferences healthcare conferences UBS Global Healthcare
Last updated: Aug 23, 2021